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One Sentence Summary: single-cell RNA-seq redefines gliomas lineages 
 
ABSTRACT  
Tumor subclasses differ in the genotypes and phenotypes of malignant cells, and in the 
composition of the tumor microenvironment (TME). Here, we dissect these influences in 
IDH-mutant gliomas, combining 14,226 single-cell RNA-seq profiles from 16 patient 
samples with bulk RNA-seq profiles from 165 patient samples. Differences in bulk 
profiles between IDH-mutant astrocytoma and oligodendroglioma can be primarily 
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explained by distinct TME and signature genetic events, whereas both tumor types 
share similar developmental hierarchies and lineages of glial differentiation. As tumor 
grade increases, we find enhanced proliferation of malignant cells, larger pools of 
undifferentiated glioma cells and increase in macrophage over microglia programs in 
TME. Our work provides a unifying model for IDH-mutant gliomas and a general 
framework to dissect the differences between human tumor subclasses. 
 
MAIN TEXT  
Tumor fitness, evolution and resistance to therapy are governed by the combination of 
selection of cancer cells with specific genotypes, by expression programs related to 
cellular phenotypes and by influences of the tumor microenvironment (TME) (1). In 
recent years, studies such as those of The Cancer Genome Atlas (TCGA) have charted 
the genetic landscape and the bulk expression states of thousands of tumors, 
identifying driver mutations and defining tumor subtypes on the basis of specific 
transcriptional profiles (2, 3). While the genetic state of tumors could be studied with 
high precision, bulk expression profiles provide only limited insight as they average 
together the phenotypic determinants of cancer programs, TME influences and intra-
tumoral genetic heterogeneity. Single-cell RNA-seq (scRNA-seq) can help address 
those challenges (4-7), but poses financial and logistic considerations, including the 
time required to accrue large cohorts of fresh tumor specimen for single cell analysis, 
especially in rare tumor types.  
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We reasoned that scRNA-seq of a limited number of representative tumors could be 
combined with existing bulk data from large cohorts to decipher these distinct effects, 
and sought to apply this approach to understand the differences between two major 
types of diffuse gliomas. In adults, diffuse gliomas are classified into three main 
categories on the basis of integrated genetic and histologic parameters: IDH-wildtype 
glioblastoma (GBM) is the most prevalent and aggressive form of the disease, while 
mutations in IDH1/2 define two major classes of gliomas: astrocytoma (IDH-A) and 
oligodendroglioma (IDH-O) (8). IDH-A and IDH-O are two distinct tumor types that differ 
in their genetics, histopathology and prognosis. Genetically, IDH-A tumors are 
characterized by TP53 and ATRX mutations, while IDH-O tumors are characterized by 
mutations in TERT promoter and loss of chromosome arms 1p and 19q, defining a 
robust genetic separation into two disease entities (2). In histopathology, IDH-A and 
IDH-O are distinct and thought to predominantly recapitulate astrocytic and 
oligodendrocytic lineages of glial differentiation, respectively. The notion that glial 
lineages differ between astrocytoma and oligodendroglioma, as implied by their names, 
originates from distinct morphology and tissue staining. However, expression of both 
oligodendroglial (e.g., OLIG2) and astrocytic (e.g., GFAP) markers can be readily 
identified in both diseases (8), mixtures of cells with histological features of neoplastic 
astrocytic and oligodendroglial cells are frequently observed within individual tumors, 
and cellular morphologies are only partially reminiscent of distinct glial cells, thus 
questioning the hypothesis of distinct glial lineages.  
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Here, we combine 9,879 scRNA-seq profiles from ten IDH-A with 4,347 single-cell 
profiles in six IDH-O and 165 TCGA bulk RNA profiles to decipher cancer cells 
genotypes and phenotypes and gain insight into TME composition across IDH-mutant 
gliomas. We find that differences in bulk profiles between IDH-A and IDH-O are 
primarily explained by signature genetic events and distinct TME composition, but not 
by distinct influences of glial lineages in the malignant cells of the two tumor types. 
Furthermore, as glioma grades increase, we observe both enhanced proliferation of 
malignant cells, a larger pool of undifferentiated glioma cells and an increase in 
macrophage over microglia programs in the TME. Our study redefines the cellular 
composition of human IDH-mutant gliomas and provides a general approach to 
decipher differences between tumor subtypes. 
 
Deciphering differences between bulk IDH-mutant glioma samples with single-cell 
RNA-seq 
We compared the expression profiles of IDH-A and IDH-O glioma using both bulk 
expression profiles from the TCGA datasets (76 IDH-O and 91 IDH-A gliomas) and 
newly measured single cell RNA-Seq profiles (Fig. 1A) from both tumor types. 
Comparing the TCGA bulk profiles, we found ~550 differentially expressed genes, 
suggesting distinct regulatory programs (2) (Fig. 1B). Since bulk profiles averaged the 
contributions of both genetically and phenotypically diverse malignant cells and 
additional diverse cells from the TME, we profiled single-cells from ten IDH-A tumors, 
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spanning clinical grades II-IV (table S1, fig. S1), retaining 6,341 single cell profiles after 
filtering out low-quality cells (Fig. 1A).  
We first sought to classify single cells into malignant and non-malignant. While genetic 
mutations may be used for such classification, mutation calling from scRNA-seq has 
limited sensitivity and specificity - and combined single-cell DNA and RNA profiling is 
not yet scalable to thousands of cells (9, 10). We thus combined two complementary 
approaches. First, gene expression clustering separated cells into three groups, 
consistent with programs of glioma cells, immune cells and oligodendrocytes (fig. S2). 
Second, since glioma cells frequently harbor large-scale chromosomal aberrations (2), 
we estimated copy number variations (CNVs) from the average expression of genes in 
large chromosomal regions within each cell (4), and validated some of our predictions 
by whole exome sequencing and DNA FISH (fig. S2; table S2) (11). Expression-based 
and CNV-based classifications were highly consistent with one another, and we used 
both criteria to identify 5,097 malignant cells (fig. S3). Our classification scheme was 
further validated by IDH mutations whose detection, while technically limited in scRNA-
seq data, was highly specific to cells classified as malignant (fig. S3; P<10-16, 
hypergeometric test).  
 
Many differences between bulk glioma samples do not stem from malignant cells 
Surprisingly, when we directly compared the IDH-A malignant cells to 4,044 malignant 
cells profiled from six IDH-O tumors (12) (Fig. 1B), only approximately half of the genes 
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that were differentially expressed based on bulk TCGA samples were also differentially 
expressed between the single malignant cells of the two tumor types (Fig. 1B, fig. S4). 
This suggests that the remaining differentially expressed genes may reflect differences 
in the TME rather than differences in the expression programs of malignant cells. 
Indeed, most of the remaining expression differences between bulk samples involved 
either microglia/macrophage-specific genes or neuron-specific genes (11), which were 
preferentially expressed in bulk IDH-A or IDH-O samples, respectively (Fig. 1C-E, fig. 
S4), suggesting influences from non-malignant cells in the bulk profiles. Differential 
expression between IDH-A and IDH-O was consistent among microglia/macrophage-
specific genes and among neuron-specific genes (Fig. 1D), allowing us to estimate the 
relative abundance of microglia/macrophages and of neuronal cells in each of the bulk 
tumors, from the average expression of these two signatures (Fig. 1E). Thus, IDH-A 
tumors are associated with more microglia/macrophages and less neuronal cells than 
IDH-O tumors, with few exceptions (Fig. 1E). Importantly, these differences are 
observed also between IDH-A and IDH-O tumors of the same clinical grade or when 
restricting the analysis to untreated tumors (fig. S4). 
 
Genetic differences account for most of expression differences between 
malignant cells 
Next, we focused on the expression differences between IDH-A and IDH-O that are 
significant both in comparison of bulk samples and of single malignant cells of the two 
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tumor types (11). We reasoned that specific genetic events might determine at least 
some of these differences. Indeed, most genes with higher expression in single 
malignant cells in IDH-A are located on chromosomes 1p and 19q, which are co-deleted 
in IDH-O (Fig. 1F). Loss-of-function of the transcriptional repressor CIC, which is 
specific to IDH-O, accounted for an additional ~10% of the expression differences (Fig. 
1F), as inferred from a CIC expression signature (11-13). We also found a limited, yet 
significant, enrichment (P=0.018, hypergeometric test) of p53 targets among genes 
more highly expressed in IDH-O tumors, consistent with a mutated TP53 in IDH-A. 
Overall, 57% of the expression differences were consistent with at least one of these 
genetic causes (Fig. 1F). Taken together, these results suggest that differences 
between bulk TCGA expression signatures of IDH-A and IDH-O primarily reflect TME 
composition and influences of genetic alterations.  
 
scRNA-seq reveals shared glial lineages in IDH-A and IDH-O  
IDH-A and IDH-O are thought to primarily recapitulate the astrocytic and 
oligodendrocytic glial lineages, respectively (8). However, the results above 
demonstrate that most differences between IDH-A and IDH-O may be accounted by 
genetics and TME, and question the hypothesis of distinct glial lineages in these 
tumors. Indeed, we observed limited differences in the expression of astrocyte-specific 
and oligodendrocyte-specific genes between IDH-A and IDH-O, either in bulk or in 
single cells profiles (Fig. 2A). Instead, the expression of these genes varied 
substantially across the cells within each of the IDH-A and IDH-O tumors. After 
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subtracting inter-tumor differences (11), principal component analysis (PCA) across all 
IDH-A cells demonstrated that PC1 and PC2 are associated with astrocyte-specific 
(PC1/2-high) and oligodendrocyte-specific (PC1/2-low) genes (Fig. 2B; table S3; P<10-
9, hypergeometric test). We refined the sets of glial lineage genes using the scRNA-seq 
data to define astrocyte-like and oligodendrocyte-like expression programs that co-vary 
across IDH-A cells (Fig. 2C; table S3) (11). These expression programs were neither 
accounted for by inter-tumor differences, nor by technical and batch effects (fig. S5A,B 
and fig. S6A), were reproduced in an analysis of 3,538 additional cells from two IDH-A 
tumors profiled with a different single cell RNA-seq protocol (fig. S5C), and were co-
expressed also among IDH-O cells (Fig. 2C). We scored individual cells in each tumor 
type for expression of these programs, and classified cells with preferential expression 
of each program, as well as intermediate cellular states (Fig. 2C). All tumors exhibited a 
wide distribution of cellular states, yet there were more IDH-A cells in intermediate 
states (Fig. 2C and fig. S6A). Interestingly, the distribution of single cell profiles from 
IDH-wildtype GBMs differed, showing a bias towards the astrocytic program, supporting 
that the cellular architecture of IDH-A and IDH-O is specific to IDH-mutant tumors and is 
not shared across all diffuse gliomas (fig. S6B). Thus, our data supports a model in 
which malignant cells in IDH-A and IDH-O share inferred lineages of glial differentiation. 
We next investigated whether the 192 genes differentially expressed between the 
malignant compartments of IDH-A and IDH-O (Fig. 1F) are shared across all malignant 
cells or whether they are specific to certain subpopulations. As expected, expression 
differences in 109 genes that can be attributed to signature genetic alterations (Fig. 1F) 
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were shared across all malignant cells (fig. S6C). However, differences between IDH-A 
and IDH-O in the expression of the remaining 83 differentially expressed genes (table 
S3) were most pronounced in differentiated tumor cells and almost completely 
abolished among the most undifferentiated cancer cells (Fig. 2D). Thus, undifferentiated 
cells from these tumor types exhibit increased similarity in gene expression programs, 
raising the possibility of shared cell-of-origin for IDH-A and IDH-O. 
To further test this hypothesis, we analyzed DNA bulk methylation patterns, as DNA 
methylation may preserve epigenetic signatures of the cell-of-origin that are not evident 
by gene expression analysis. We found high similarity in DNA methylation between IDH-
A and IDH-O compared to both IDH-wildtype gliomas and to IDH-mutant non-glioma 
tumors (fig. S7). While DNA methylation is highly influenced by the IDH mutation, this 
high similarity is consistent with a shared histogenesis of IDH-A and IDH-O.  
 
Undifferentiated glioma cells are associated with proliferation and a shared 
stemness program 
The high degree of expression similarity between undifferentiated cells in IDH-A and 
IDH-O and the possibility that these might reflect a stem/progenitor cell phenotype 
prompted us to further investigate their developmental programs. We previously 
identified cancer stem-like cells in IDH-O that display neural stem/progenitor programs 
and are highly enriched in cell cycle programs (12). Generalizing this finding across all 
IDH-mutant gliomas classes, we identified cycling cells on the basis of the expression of 
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consensus cell cycle signatures (fig. S8A) (11, 12, 14), and found that in both IDH-A 
and IDH-O only a small proportion of cells are proliferating (~4% on average in our 
cohort), and that there is an inverse correlation between proliferation and differentiation 
(Fig. 3A). Remarkably, the fraction of cycling cells for a given state of differentiation is 
similar between IDH-A and IDH-O (Fig. 3A). This supports a model in which 
proliferation and cell identity are tightly coupled in IDH-mutant tumors. 
We derived a gene signature of the undifferentiated cells (excluding cycling cells) 
across the IDH-A and IDH-O tumors. Ninety genes were enriched within undifferentiated 
cells of at least three distinct tumors and were examined further for their co-expression 
among undifferentiated IDH-A and IDH-O cells (Fig. 3B). We defined a putative glioma 
stemness program as the subset of genes (Fig. 3C) that are both enriched and co-
expressed in undifferentiated cells of both IDH-A and IDH-O. Indeed, this program 
includes neurodevelopmental transcription factors (e.g., SOX4, SOX11 and TCF4), and 
is consistent with the expression program of human neural stem cells (NSCs) and 
neural progenitor cells (NPCs) and with a program we highlighted in IDH-O (fig. S9). 
We validated this tumor architecture in IDH-A tissues in fourteen additional cases (table 
S1), showing in each tumor: (i) two glial lineages of cancer cells differentiation, (ii) 
mutually exclusive expression of cycling (by Ki-67 staining) and differentiation (by ApoE 
expression) markers, and (iii) co-expression of cycling (Ki-67) and putative stem cell 
(SOX4) markers (Fig. 3D, table S1). This architecture has also been validated in a 
cohort of sixteen IDH-O (12). 
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Changes in tumor architecture associated with tumor grade and genetic 
subclones  
While IDH-A and IDH-O share the same stem/progenitor programs and putative 
lineages of glial differentiation, our analyses reveal three inter-related differences: (1) 
the overall fraction of cycling cells (Fig. S8), and (2) of undifferentiated cells (Fig. 2D) 
are higher in our IDH-A cases; and (3) the two lineage scores are inversely related in 
IDH-O, consistent with a differentiation process in which one lineage represses the 
other, a relationship not observed in IDH-A (fig. S6D-E).  
Notably, all three aspects vary significantly within the IDH-A tumors and correlate with 
tumor grade, such that higher grade tumors tend to have more cycling and 
undifferentiated cells and a more limited association between lineage programs (Fig. 
4A, fig. S10A-B). This provides a molecular fingerprint for tumor progression, as IDH-A 
tumors begin as grade II lesions and progress to grade III and IV. We validated the 
correlation between the frequency of cycling malignant cells (as reflected by the cell 
cycle program) and tumor grade with analysis of bulk TCGA samples (fig. S10C).  
We hypothesized that the observed fingerprint of tumor grade-associated changes 
might also be reflected in clonal evolution, whereby genetically distinct subclones within 
the same tumor vary in their frequency of cycling and undifferentiated cells, with 
selection favoring the more aggressive subclones. To study genetic intra-tumoral 
heterogeneity, we inferred CNVs with single cell expression profiles (fig. S1B), and 
predicted subclones in three of our tumors, MGH44, MGH57, and MGH103 (Fig. 4B-C, 
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fig. S2, S11). In each of these cases, while the overall tumor architecture was 
preserved across clones, we also observed variability either in the fraction of cycling 
cells or in differentiation patterns (Fig. 4D-E, fig. S11). Overall, these cases together 
with two IDH-O cases (12), demonstrate that patterns of differentiation and proliferation 
can be partially modulated by genetics and be subjected to selection.  Future studies 
should further investigate the modulation of our inferred cellular architecture by genetic 
evolution. 
 
The microglia to macrophage balance in the glioma TME 
Finally, we analyzed the diversity of microglia/macrophage cells, the predominant 
subset of non-malignant cells in the TME (n= 1,043 in IDH-A and 246 in IDH-O) using 
PCA (fig. S12). The second PC (PC2) reflected an inflammatory program consisting of 
cytokines (IL1, IL8, TNF), chemokines (CCL3, CCL4), NFKB-related genes (REL, 
NFKBIA, NFKBIZ) and immediate early genes (JUNB, FOSB, EGR3, IER3, ATF3). The 
program was active in most microglia/macrophage cells across IDH-A and IDH-O 
tumors and is similar to a reported program in IDH-O (12) (table S3). PC1 highlighted 
two mutually opposing programs, which were highly consistent with microglia (PC1-
high) and macrophage (PC1-low) expression programs (Fig. 4A, table S3). Top PC1-
high genes included microglia markers, such as CX3CR1, P2RY12 and P2RY13 (15), 
whereas CD163, TGFBI and F13A1 were among the PC1-low genes and are more 
highly expressed in diverse macrophage populations than in microglia (16) (Fig. 4A). 
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Thus, PC1 may correspond to the differences between brain-resident microglia, and 
infiltrating macrophages that reach the tumor through the circulation and must pass 
through the blood-brain barrier.  
 
However, scoring cells by the relative expression of microglia-specific to macrophage-
specific genes revealed a continuum, rather than a bimodal distribution (Fig. 4B), which 
is difficult to account for by a simple model of two populations (microglia and 
macrophages) and suggests additional influences on these expression programs. 
Furthermore, even the top macrophage-like cells in gliomas have lower macrophage 
scores compared to macrophages from melanoma tumors (Fig. 4C) (5). Thus, the 
glioma microenvironment might have altered the expression profiles of macrophages, 
thereby decreasing their difference from microglia. Moreover, microglia/macrophages 
from each individual tumor had a limited range of scores, with some tumors biased 
towards macrophage-like cells (e.g., MGH42) and others towards microglia-like cells 
(e.g., MGH56) (Fig. 4C). This indicates that specific properties of the microenvironment 
of each tumor may be dominant over the immune cell-of-origin with respect to 
macrophage-like and microglia-like expression states, consistent with recent studies 
(15).  
This observed inter-tumor variability in macrophage/microglia states correlated with 
grade, such that cells from higher-grade tumors were preferentially associated with 
macrophage-like expression states. We validated this association by comparing the 
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expression of macrophage-specific and microglia-specific genes across grades in bulk 
TCGA IDH-A and IDH-O tumors (Fig. 4D) and by RNA in situ hybridization (ISH) for 
CX3CR1 and CD163 in our own cohort (Fig. 4F). We also observed some cells that co-
express microglia and macrophage programs in tumors, supporting our hypothesis of a 
continuum of microglia-like to macrophage-like states (Fig. 4F). These results suggest 
that early in their development, gliomas primarily contain brain-resident microglia-like 
cells, while macrophage-like programs are associated with higher grades, possibly 
coinciding with other grade-associated changes, such as increased angiogenesis and 
alterations of the blood brain barrier.  
Accordingly, this effect may parallel changes in tumor vascularity. We derived a 
signature of endothelial-specific genes (11) and used their average expression to 
estimate the abundance of endothelial cells in each bulk tumor. This endothelial 
signature is correlated with the macrophage-specific, but not with microglia-specific, 
programs across IDH-O and IDH-A tumors (Fig. 4E). Moreover, the endothelial 
signature increases with tumor grade, paralleling changes in the macrophage-specific, 
but not microglia-specific, expression programs (Fig. 4D). While the endothelial 
program correlates with variability in the macrophage-like expression program between 
cells it does not account for the variability in the overall proportion of microglia and 
macrophages. IDH-A tumors have a considerably higher proportion of 
microglia+macrophage cells than IDH-O tumors, as noted above (Fig. 1C), and this 
difference is not accounted for by endothelial cells or by grade (Fig. 4D).  
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To search for additional mechanisms that might regulate infiltration of 
macrophage/microglia cells into the tumor we searched for genes that are not 
expressed by macrophage/microglia, but are correlated with the inferred abundance of 
macrophage/microglia cells across bulk tumor samples. We found 24 genes correlated 
with both microglia and macrophage expression across IDH-A tumors, and separately, 
across IDH-O tumors (fig. S134A, top). Although these analyses were performed within 
a tumor type and thus were not directly influenced by differences between IDH-A and 
IDH-O, these genes were preferentially expressed in IDH-A (fig. S13A, bottom), 
consistent with the increased macrophage/microglia signatures in IDH-A. While we 
cannot determine if these associations are causal (i.e., we cannot distinguish whether 
these genes influence, or are influenced by, immune infiltration, or whether both are 
affected by a third hidden factor), the ability of this expression program to predict the 
extent of macrophage/microglia infiltration across tumors and tumor types (fig. S13B) 
suggests interactions between immune infiltration and other cells in the tumor. 
Interestingly, three of those genes were components of the complement system – a 
specialized arm of the innate immune system – which we recently observed in a similar 
analysis of fibroblast-immune cell interactions in melanoma (5).  
Taken together, our observations (i) define microglia and macrophage programs in 
gliomas at single-cell resolution, (ii) associate the macrophage, but not the microglia 
program, with clinical grade and increased vascularity, (iii) highlight a continuity in 
transcriptional programs of microglia/macrophage in tumors (rather than a bimodal 
distribution), suggesting plasticity of cellular states, (iv) reveal an overall increase in 
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microglia/macrophage infiltration in IDH-A compared to IDH-O, and (v) define a tumor  
expression signature associated with increased microglia/macrophage infiltration.    
 
Discussion 
Our approach provides a general framework to decouple cancer cell genotypes, 
phenotypes, and the composition of the TME in tumors, combining single-cell analysis 
of a limited set of representative tumors with bulk samples collected for larger cohorts, 
such as those from TCGA. In IDH-mutant gliomas, our approach uncovers shared 
neural developmental programs and putative lineages of glial differentiation in IDH-A 
and IDH-O. Thus, IDH-mutant gliomas are primarily composed of three subpopulations 
of malignant cells including non-proliferating differentiated cells of two glial lineages, 
and proliferative undifferentiated cells that resemble neural stem/progenitor cells. The 
shared glial lineages and developmental hierarchies suggest a common progenitor for 
all IDH-mutant gliomas with NSC/NPC-like programs, shedding light on a long-standing 
debate in gliomagenesis (17). 
Our study thus represents a shift in our understanding of the histogenesis of glial tumors 
and supports a model where IDH-mutant gliomas subclasses share developmental 
programs and putative lineages of glial differentiation, but differ primarily by genetic 
mutations and TME composition; all IDH-mutant gliomas we examined at single cell 
resolution, including 10 IDH-A and 6 IDH-O tumors, defined by genetics and 
histopathology, contained malignant cells recapitulating oligodendrocytic-like and 
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astrocytic-like glial programs as well as a neural precursor program. While our cohort is 
fairly limited, our cases have had little selection bias (consecutive cases operated at our 
institution), and our observations have been validated in larger cohorts by tissue 
staining and by analysis of the TCGA datasets.  
Given the similar developmental architecture of IDH-A and IDH-O, the morphological 
differences between these two entities might be linked to genetic differences between 
IDH-A and IDH-O and to TME composition. Accordingly, at least two genes involved in 
cytoskeleton and cell shape are downregulated by IDH-O-specific mutations: (I) glial 
fibrillary acidic protein (GFAP), a marker commonly used to assess astrocytic lineage in 
histopathology, is positively regulated by CIC (12) and thus more highly expressed in 
IDH-A than IDH-O (table S3); and (II) RHOC, encoding RhoC GTPase, a well-known 
regulator of cell shape and motility (18, 19) is located on chromosome arm 1p and 
therefore more highly expressed in IDH-A (table S3). Thus, signature genetic events 
might influence the morphology of cancer cells and underlie at least some of the 
histopathologic differences. 
We also found a considerable difference in the TME composition of IDH-mutant 
gliomas, whereby IDH-A is enriched with microglia/macrophages signatures. These 
differences in TME composition may also at least in part be driven by genetic 
influences. For example, TP53 (mutated only in IDH-A) has been implicated with effects 
on inflammation and immune infiltration (20).  
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While our data supports a shared architecture for all IDH-mutant gliomas, the cellular 
composition in other diffuse gliomas might differ. Indeed, we were not able to clearly 
identify a similar architecture in IDH-wildtype GBM. As much of the literature on putative 
glial lineages of malignant cells of gliomas preceded the discovery of the IDH1/2 
mutations, IDH-wildtype GBM might have confounded analysis in those studies. By 
analyzing IDH-mutant gliomas of different clinical grades (spanning II-IV) at single cell 
resolution, we identified a potential molecular fingerprint of tumor progression, with 
support in TCGA datasets; our analyses suggest that high-grade lesions show 
increased proliferation, larger pools of undifferentiated cells, partially aberrant 
differentiation programs and increased infiltration by macrophages over resident 
microglia. Finally, from a therapeutic standpoint, our data raise the possibility that 
triggering cellular differentiation could arrest the growth of these tumors. By shedding 
light on the cellular composition of IDH-mutant gliomas, our data offer opportunities for 
the design of immunotherapies targeting cancer cells phenotypes, a potentially novel 
avenue in the treatment of these currently incurable malignancies. 
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Figure Legends  
 
Figure 1. Expression differences between IDH-A and IDH-O are governed by the 
tumor microenvironment and genetics.  (A) Workflow: Freshly-resected tumors were 
dissociated to single cell suspension, FACS-sorted and profiled by SmartSeq2 in 96-
well plates. (B) Differential expression between IDH-A and IDH-O across bulk TCGA 
tumors (left), across single cells (middle) and the averages from each of these two 
analyses (right). (C) Differentially expressed genes by bulk analysis include 
microglia/macrophage-specific genes (left column) and neuron-specific genes (right 
column). (D) Distribution of expression differences between bulk IDH-A and IDH-O 
samples for microglia/macrophage-specific genes (black) and neuron-specific genes 
(grey). (E) Microglia/macrophage scores (X-axis) and neuron scores (Y-axis) (11), for 
bulk IDH-O (blue) and IDH-A (purple) tumors. (F) Left: Differentially expressed genes 
which are not microglia/macrophage-specific or neuron-specific assigned  to four 
categories (top to bottom rows)of genetic influences (11): (i) genes residing in 
chromosome arms 1p or 19q, (ii) genes activated or (iii) repressed by CIC, and (iv) P53 
target genes. Right: Observed and expected percentages of IDH-A specific genes 
assigned to the first two categories and IDH-O specific genes assigned to the last two 
categories. Expected percentages were defined by analysis of all genes rather than only 
the IDH-A and IDH-O specific genes.   
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Figure 2. Glial lineages are shared among IDH-A and IDH-O. (A) Average 
expression levels of oligodendrocytic-specific (light blue) and astrocytic-specific (black) 
genes across all IDH-A (Y axis) and IDH-O (X axis) malignant cells. (B) Correlations of 
oligodendrocytic-specific (light blue) and astrocytic-specific (black) genes with PC1 (X 
axis) and PC2 (Y axis) from a PCA of all IDH-A malignant cells. (C) Classification of 
malignant cells (columns) from IDH-A (left panel) and IDH-O (right panel), by the 
differential expression of 50 oligodendrocytic and 50 astrocytic genes. Bottom: relative 
expression of the 100 genes (rows); Top: significance of differential expression (-
log10(P-value of a t-test)) between oligodendrocytic and astrocytic genes. Cells were 
sorted by significance from the most oligodendrocytic-like to the most astrocytic-like 
cells; dashed lines indicate a significance threshold of P<0.01. (D) For each malignant 
cell in IDH-A (purple) and IDH-O (blue), we present its differentiation scores (X-axis,  
maximum of oligodendrocytic and astrocytic scores) vs. the average expression of IDH-
A (left) or IDH-O (right) specific genes (Y axis, excluding those genes exhibiting 
differential expression due to genetic alterations). Lines indicate the corresponding local 
weighted smoothing regression (LOWESS), demonstrating the decreased differences 
between IDH-A and IDH-O programs in cells with low glial differentiation scores.   
 
Figure 3. Undifferentiated cells in IDH-A and IDH-O are associated with cycling 
cells and a putative stemness program. (A) Percentage of cycling cells (Y axis) in 
sliding windows of 200 cells ranked by differentiation scores (X axis) for either IDH-A 
(purple) or IDH-O (blue) malignant cells. (B) Pearson correlations (color bar) between 
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the expression profiles of ninety genes preferentially expressed in undifferentiated cells, 
across IDH-A (top) and IDH-O (bottom) undifferentiated cells. Genes are ordered by 
their correlation with the highest-scoring cluster in each analysis (11). (C) Pearson 
correlations of the ninety genes in (B) with the highest-scoring clusters in (B) in IDH-A 
(X-axis) and IDH-O (Y-axis). The top consistent genes are marked. (D) In situ RNA 
hybridization (ISH) shows mutually exclusive expression of astrocytic (APOE, blue) and 
oligodendrocytic (APOD, red) lineage markers; mutually exclusive expression of 
astrocytic and proliferation (Ki67, red, arrow) markers; and co-expression of proliferation 
and stem/progenitor (SOX4, blue, arrow) markers. 
 
Figure 4. Analysis of tumor architecture by tumor grade and in genetic subclones. 
(A) The percentage of cycling cells (top), of undifferentiated cells (middle) and the 
negative correlation between the two lineage scores (bottom) are all associated with 
tumor grade (P<0.05, one-way ANOVA). For each feature, bars show the average value 
across groups of tumors defined by tumor type and grade. Error-bars indicate standard 
error. (B-C) CNV inference in MGH103 (B) and MGH57 (C) reveals large-scale CNVs 
which vary between cells of the same tumor. Cells were clustered based on their CNV 
patterns at specific chromosomal regions (black lines at top) to define putative 
subclones. (D,E) Comparison of the two lineage scores (left) and percentage of cycling 
cells (right) between the two subclones indicated for MGH103 (D) and for MGH57 (E). 
Significant differences are indicated (* - P<0.05, ** - P<0.001**; Kolmogorov-Smirnov 
test for lineages and hypergeometric test for cell cycle). 
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Figure 5. Microglia and macrophages across IDH-mutant gliomas.  (A) Microglia 
(Y-axis) and macrophages (X-axis) expression levels (21) of genes with high (red) and 
low (blue) PC1-scores from PCA of tumor microglia/macrophages (B) Top: distribution 
of scores by average expression of microglia (PC1-high) vs. macrophage (PC1-low) 
genes (11). Bottom: differential expression of selected microglia- and macrophage-
specific genes among all cells ranked by the scores at top. (C) Fraction (color code) of 
cells in bins of scores, as defined in (B, top) for each glioma (rows); Macrophages from 
melanoma (5) are included for reference (top row). Right: tumor grades. (D) Average 
endothelial scores (X-axis) vs. macrophage (left) or microglia (right) (Y-axis) across 
IDH-A (purple) and IDH-O (blue) tumors (gray, grade II; black, grade III; red, grade IV). 
Arrows indicate grade-specific changes associated with increased expression of 
endothelial program. (E) Correlation between endothelial scores and 
macrophage/microglia scores across all IDH-A (purple) or IDH-O (blue) bulk TCGA 
tumors. (F) In situ RNA hybridization for microglia (CX3CR1, blue) and macrophage 
(CD163, red) markers. Left panel: MGH56 contains predominantly microglia-like cells. 
Central panels:  MGH43 contains microglia-like cells, macrophage-like cells (blood 
vessels, arrows) and cells expressing both markers (arrows). Right panel: MGH42 
stains exclusively for CD163. 
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